Keros Therapeutics, Inc. (KROS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 11.8 |
| Open | 11.55 |
| Day High | 11.61 |
| Day Low | 11 |
| 52-Week High | 22.55 |
| 52-Week Low | 9.69 |
| Volume | 250,130 |
| Average Volume | 313,368 |
| Market Cap | 355.18M |
| PE | -3.69 |
| EPS | -3.01 |
| Moving Average 50 Days | 10.99 |
| Moving Average 200 Days | 14.65 |
| Change | -0.7 |
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
GlobeNewswire Inc.
Mar 09, 2026 12:00 PM GMT
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range o
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
GlobeNewswire Inc.
Mar 09, 2026 12:00 PM GMT
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range o
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
GlobeNewswire Inc.
Mar 04, 2026 9:01 PM GMT
LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range o